136 related articles for article (PubMed ID: 15274669)
1. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract.
Lanas A
Aliment Pharmacol Ther; 2004 Aug; 20(3):321-31. PubMed ID: 15274669
[TBL] [Abstract][Full Text] [Related]
2. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
Lanas A; Hunt R
Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
[TBL] [Abstract][Full Text] [Related]
3. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A; Ferrandez A
Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
[TBL] [Abstract][Full Text] [Related]
4. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
5. Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users.
Murthy SK; Kauldher S; Targownik LE
Aliment Pharmacol Ther; 2006 May; 23(9):1365-72. PubMed ID: 16629943
[TBL] [Abstract][Full Text] [Related]
6. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy.
Walan A; Wahlqvist P
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S79-88. PubMed ID: 10379474
[TBL] [Abstract][Full Text] [Related]
8. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
[TBL] [Abstract][Full Text] [Related]
9. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
Lanas A
Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
[TBL] [Abstract][Full Text] [Related]
12. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice.
Lanas A; García-Rodríguez LA; Polo-Tomás M; Ponce M; Alonso-Abreu I; Perez-Aisa MA; Perez-Gisbert J; Bujanda L; Castro M; Muñoz M; Rodrigo L; Calvet X; Del-Pino D; Garcia S
Am J Gastroenterol; 2009 Jul; 104(7):1633-41. PubMed ID: 19574968
[TBL] [Abstract][Full Text] [Related]
13. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs.
Pilotto A; Franceschi M; Vitale DF; Zaninelli A; Masotti G; Rengo F; ;
Aliment Pharmacol Ther; 2005 Jul; 22(2):147-55. PubMed ID: 16011673
[TBL] [Abstract][Full Text] [Related]
14. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
Vonkeman HE; Fernandes RW; van der Palen J; van Roon EN; van de Laar MA
Arthritis Res Ther; 2007; 9(3):R52. PubMed ID: 17521422
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
17. [Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects].
Lanas A
Med Clin (Barc); 2000; 114 Suppl 3():46-53. PubMed ID: 10994564
[TBL] [Abstract][Full Text] [Related]
18. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.
Morant SV; Shield MJ; Davey PG; MacDonald TM
Pharmacoepidemiol Drug Saf; 2002; 11(5):393-400. PubMed ID: 12271881
[TBL] [Abstract][Full Text] [Related]
19. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors.
Thomsen RW; Riis A; Christensen S; McLaughlin JK; Sørensen HT
Aliment Pharmacol Ther; 2006 Nov; 24(10):1431-8. PubMed ID: 17032286
[TBL] [Abstract][Full Text] [Related]
20. NSAID-related upper gastrointestinal bleeding: are risk factors considered during prophylaxis?
Dincer D; Duman A; Dikici H; Arici C; Suleymanlar I; Isitan F
Int J Clin Pract; 2006 May; 60(5):546-8. PubMed ID: 16700851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
